June 6, 2017 / 1:11 PM / 2 months ago

BRIEF-Crispr Therapeutics signs service agreement with Masthercell SA

June 6 (Reuters) - Crispr Therapeutics Ag:

* Crispr Therapeutics and Masthercell SA sign service agreement for the development and manufacturing of allogeneic cell therapies

* Crispr Therapeutics AG says masthercell will be responsible for development and CGMP manufacturing of CTX101 for use in clinical studies

* CTX101 is an allogeneic car T-cell therapy currently in development by Crispr therapeutics for treatment of CD19 positive malignancies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below